The following chart illustrates the various bottlenecks restraining the development of France's pharmaceutical industry, including lack of investment, fewer new molecules than other European countries, disappointing performance in biological drugs, and long waiting times for drug approval. Bottlenecks Click here to read more articles and interviews from France, and to download the latest free pharma report on the country.